Data provide validation of the Vaxxinity (VAXX) platform’s ability to selectively target aggregated, toxic forms of neurodegenerative proteins UB-312 is designed to target aggregated forms of aSyn, ...

The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...

Parkinson’s disease is associated with the buildup of a particular brain protein that currently has no approved therapies addressing it. Novartis was among the companies pursuing this target, but its ...

Research suggests that the Mediterranean diet and certain others can lower Parkinson's risk, while those high in ...

Professor, Aarhus University, Dept. of Biomedicine (West), Director, DANDRITE, Danish Research Institute of Translational Neuroscience, (Nordic EMBL partnership for Molecular Medicine). Co-founder and ...

A novel strategy that combines computational and experimental approaches has allowed researchers at Baylor College of ...

– The sunbird αSyn™ assay accurately classified Parkinson’s disease-positive blood samples with 81% accuracy through the direct detection of EV-bound aggregated alpha-synuclein proteins – – With no ...

Their study, "Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson's disease,” was recently published in Nature Communications. The study ...

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, ...

Researchers at Baylor College of Medicine have discovered a potential new strategy to fight back against Alzheimer's and Parkinson's diseases, conditions that are linked to the toxic accumulation of ...